BlackRock
INKT icon

BlackRock’s MiNK Therapeutics INKT Stock Holding History

BlackRock’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.3K Hold
6,203
– – ﹤0.01% 5060
2025
Q4 		$69.2K Sell
6,203
-95
-2% -$1.23K ﹤0.01% 4981
2025
Q3 		$88.2K Sell
6,298
-1,123
-15% -$18K ﹤0.01% 4858
2025
Q2 		$54.8K Sell
7,421
-1,357
-15% -$10.2K ﹤0.01% 4972
2025
Q1 		$75.8K Sell
8,778
-50
-0.6% -$445 ﹤0.01% 4828
2024
Q4 		$61.5K Buy
8,828
+15
+0.2% +$102 ﹤0.01% 4897
2024
Q3 		$66.1K Buy
8,813
+93
+1% +$789 ﹤0.01% 4749
2024
Q2 		$82.8K Buy
8,720
+1,105
+15% +$10.8K ﹤0.01% 4747
2024
Q1 		$69.2K Sell
7,615
-31
-0.4% -$288 ﹤0.01% 4811
2023
Q4 		$81.8K Sell
7,646
-404
-5% -$4.22K ﹤0.01% 4864
2023
Q3 		$88.5K Sell
8,050
-153
-2% -$2.49K ﹤0.01% 4880
2023
Q2 		$172K Buy
8,203
+7,117
+655% +$143K ﹤0.01% 4771
2023
Q1 		$20.6K Buy
1,086
+36
+3% +$779 ﹤0.01% 5254
2022
Q4 		$27.4K Buy
1,050
+49
+5% +$1.15K ﹤0.01% 5342
2022
Q3 		$21K Buy
1,001
+337
+51% +$6.64K ﹤0.01% 5502
2022
Q2 		$10K Sell
664
-1,100
-62% -$20.7K ﹤0.01% 5625
2022
Q1 		$40K Buy
1,764
+724
+70% +$21.7K ﹤0.01% 5457
2021
Q4 		$46K Buy
+1,040
New +$124K ﹤0.01% 5416

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock's INKT Position: Q1 2026 in Review

BlackRock held its MiNK Therapeutics (INKT) position steady in Q1 2026 at 6,203 shares worth $65.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5060.

BlackRock first reported a position in INKT in Q4 2021 and has held it in 18 quarters since. The position peaked at $172K in Q2 2023. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • BlackRock held 6,203 shares of MiNK Therapeutics worth $65.3K as of Q1 2026.
  • BlackRock left its MiNK Therapeutics share count unchanged in Q1 2026.
  • MiNK Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #5060 holding.
  • BlackRock first reported a position in MiNK Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • BlackRock's MiNK Therapeutics position peaked at $172K in Q2 2023.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.